Rituximab for Pediatric Renal Transplant Rejection
|Kidney Transplantation||Drug: Rituximab for transplant rejection||Phase 2 Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Prospective Open-Labeled Randomized Study of Rituximab Versus Standard of Care, for Treatment of Acute Allograft Rejection in Pediatric Renal Transplantation|
- Rituximab safety in pediatric patients
- resolution fo graft rejection
|Study Start Date:||June 2005|
|Estimated Study Completion Date:||August 2007|
Twenty kidney transplant recipients who are being cared for at Stanford University and UCLA and are between the ages of 2-21, can be considered for participation in this research if they are having an acute rejection episode. After a biopsy is done and the diagnosis of acute rejection is made, ten patients will be randomly enrolled in the group to be treated with Rituximab and steroid pulses. Ten children will be enrolled as the control group, receiving standard of care for acute transplant rejection.
Assignment will be based on a 1:1 randomization scheme. That means two patients will be assigned to the group of patients receiving steroid pulsing and 4 doses of Rituximab. The third patient would be assigned to the group receiving steroid pulses and adjustment in immunosuppression medications which is the standard of care at Stanford University.
The dose of Rituximab that will be given is 375 mg/m2 and is administered through an IV. Additional doses of Rituximab will be administered on a weekly basis. A total of four doses will be given.
If the acute rejection does not resolve by one-week, patients in both groups have the option of receiving polyclonal antibody therapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00697996
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||Minnie M. Sarwal||Stanford University|